Q-omics provides the consensus-scored ZNF197 profile across patient tissues and cancer cell-line models. ZNF197 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF197 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZNF197 RNA expression shows 21,314 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where ZNF197 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF197 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF197 survival associations across molecular data types. ZNF197 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF197 RNA expression–survival associations across cancer types. High ZNF197 expression shows unfavorable associations in KICH and LUSC, but favorable associations in KIRC, UCS, BRCA and THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF197 RNA expression.
This table summarizes ZNF197 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF197. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF197 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, BLCA, CHOL and STAD. The THCA box plot shows higher ZNF197 RNA expression in normal versus tumor tissue (log2 FC = −0.735, t-test p < 0.001).
This table shows molecular features associated with ZNF197 in patient tissues and cancer cell lines. In patient samples, ZNF197 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF197 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
